Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NU6102 is a selective and potent ATP-competitive CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK2/cyclinA3, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 107.00 | |
10 mg | In stock | $ 156.00 | |
25 mg | In stock | $ 258.00 | |
50 mg | In stock | $ 385.00 | |
100 mg | In stock | $ 572.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 128.00 |
Description | NU6102 is a selective and potent ATP-competitive CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK2/cyclinA3, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer. |
Targets&IC50 | PDK1:0.8 μM, DYRK1A:0.9 μM, CDK4:1.6 μM, CDK2-CyclinA3:5.4 nM, CDK1-CyclinB:9.5 nM |
In vitro | Treatment with NU6102 (0-30 μM; 1-24 hours) induces G2 arrest, inhibition of Rb phosphorylation, and cytotoxicity (LC50 2.6 μM for a 24-hour exposure) in SKUT-1B cells[3]. NU6102 inhibits cell growth and causes cell cycle phase arrest in human breast cancer cell lines, displaying G2/M arrest in asynchronously growing cell lines and G1/S arrest in cells released from serum starvation, and in Xenopus nuclei in a time-dependent manner[3]. Moreover, NU6102 selectively inhibits the growth of CDK2 WT (wild type) compared to KO MEFs (knockout mouse embryo fibroblasts) with a GI50 of 14 μM versus >30 μM[3]. |
In vivo | The pharmacokinetics of NU6102 are determined in Balb/C mice following i.v. and i.p. administration. Due to the limited solubility of NU6102, the maximum administrable dose is 1 mg/kg i.v. and 10 mg/kg i.p. NU6102 is liberated following either i.p. or i.v. administration of NU6301. After i.v. administration, peak plasma levels of 12 μM NU6102 are observed 5 minutes post-administration, while the peak concentration achieved with the maximum administrable dose of NU6102 i.v. is 0.92 μM. The plasma half-life of NU6102 liberated following NU6301 administration is 42 minutes after i.p. and 10 minutes after i.v. administration[3]. |
Synonyms | NU-6102, NU 6102 |
Molecular Weight | 402.47 |
Formula | C18H22N6O3S |
CAS No. | 444722-95-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL(198.77 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NU6102 444722-95-6 Cell Cycle/Checkpoint CDK NU-6102 NU 6102 inhibitor inhibit